Chondrosarcoma

Chondrosarcoma is a malignant bone tumor characterized by the production of cartilage matrix. It is one of the more common primary malignant bone tumors in adults.

Chondrosarcoma is not a single uniform disease. It includes several biologically distinct subtypes, including conventional, dedifferentiated, mesenchymal, clear cell, and periosteal chondrosarcoma.

Conventional chondrosarcoma is the most common type and can be further graded according to its microscopic features. In general, higher-grade tumors have a greater risk of local recurrence and distant metastasis.

Some chondrosarcomas arise directly in bone, while others develop from a pre-existing cartilage lesion such as an osteochondroma or enchondroma. The terms “primary” and “secondary” therefore describe how the tumor developed rather than how advanced it is.

Some low-grade central cartilage tumors arising in the long bones of the limbs are now classified as atypical cartilaginous tumors (ACTs). Their behavior and management can differ from chondrosarcomas arising in axial sites such as the pelvis.

The exact cause of most chondrosarcomas is unknown.

Some tumors carry specific molecular alterations. For example, changes involving IDH1 or IDH2 can be found in subsets of conventional central chondrosarcoma, although these changes are usually acquired within the tumor and do not mean that the cancer was inherited.

Conditions associated with increased risk include:

• Hereditary multiple osteochondromas

• Ollier disease

• Maffucci syndrome

• Certain pre-existing enchondromas or osteochondromas

• A small number of other cartilage disorders

Patients with inherited or multiple cartilage tumors should seek evaluation if an existing lesion becomes increasingly painful, grows rapidly, or changes in other concerning ways.

The most common symptom of chondrosarcoma is persistent or gradually worsening pain at the tumor site.

Unlike ordinary musculoskeletal pain, the discomfort may continue for weeks or months and may persist even at rest. Some patients also experience pain at night.

Other possible symptoms include:

• Local swelling or a slowly enlarging mass

• Tenderness

• Reduced movement near a joint

• Loss of function in the affected limb

• Radiating pain, numbness, or weakness if the tumor compresses nearby nerves

• A pathologic fracture in some patients

Tumors arising in the pelvis, spine, or other deep locations may not produce a noticeable mass early, so persistent pain may be the main symptom.

Diagnosis requires a combination of imaging and pathologic evaluation, ideally by a team experienced in bone tumors.

X-rays can show bone destruction, changes in the cortex, and characteristic calcification within cartilage matrix.

CT is particularly useful for evaluating cortical destruction, subtle calcification, and the relationship of the tumor to surrounding bone.

MRI is important for defining the extent of the tumor within the bone and surrounding soft tissues and for assessing its relationship to nearby joints, nerves, and blood vessels.

Staging is also needed when malignancy is suspected. The lungs are a common site of distant metastasis, so chest CT is often part of the evaluation. Other imaging may be used depending on the tumor subtype, grade, and clinical situation.

A biopsy is generally required to establish the diagnosis.

Biopsy should be planned after imaging and in coordination with the bone tumor team that may perform the definitive surgery. The biopsy tract can affect later surgical resection, so careful planning is important.

Core needle biopsy is commonly used, while open biopsy may be appropriate in selected cases.

Surgery

For resectable chondrosarcoma, the goal is complete tumor removal with appropriate surgical margins while preserving as much function as safely possible.

The extent of surgery varies widely.

Some low-grade cartilage tumors in the limbs may be treated with more limited local procedures, while higher-grade tumors, pelvic tumors, or more extensive disease may require wider resection.

Amputation is not determined simply by tumor grade. The key questions are whether the tumor can be completely removed with adequate margins and whether a functional limb can be preserved.

Chemotherapy

The statement that “chondrosarcoma is resistant to chemotherapy” applies mainly to conventional chondrosarcoma and should not be generalized to every subtype.

Conventional chondrosarcoma tends to respond poorly to standard cytotoxic chemotherapy, so chemotherapy is not routinely used for most localized cases.

Mesenchymal chondrosarcoma is an important exception. It tends to occur in younger patients, behaves more aggressively, and may be more sensitive to chemotherapy. Treatment may include multi-agent chemotherapy together with surgery and, in selected cases, radiation therapy.

Systemic chemotherapy may also be considered for dedifferentiated chondrosarcoma, although its effectiveness remains limited and treatment should be individualized.

Radiation Therapy

Conventional chondrosarcoma is relatively resistant to standard radiation therapy, so radiation is generally not the primary treatment when the tumor can be completely removed surgically.

However, radiation can still have an important role in selected cases, including tumors that cannot be completely removed, tumors with inadequate surgical margins, local recurrences, or tumors arising in anatomically difficult locations such as the spine or skull base.

Recurrent or Metastatic Chondrosarcoma

The lungs are one of the most common sites of distant spread, and the risk of metastasis depends strongly on tumor subtype and grade.

For a localized recurrence or a limited number of resectable metastases, additional surgery may still be considered.

When complete resection is not possible, systemic treatment depends on the specific subtype, and participation in a clinical trial should be considered whenever appropriate.

IDH1 and IDH2 alterations occur in subsets of conventional chondrosarcoma, and targeted approaches are being actively studied. The IDH1 inhibitor ivosidenib has shown disease-control activity in early clinical studies, but as of 2026 it is not FDA-approved specifically for chondrosarcoma, and a phase III trial in unresectable or metastatic IDH1-mutant conventional chondrosarcoma is ongoing.